Understanding the molecular changes in tumors in response to anti-VEGF chemotherapy is crucial for optimization of the treatment strategy for metastatic colorectal cancer. We prospectively investigated changes in the amount and constitution of circulating tumor DNA (ctDNA) in serial peripheral blood samples during chemotherapy. Sixty-one plasma samples taken at different time points (baseline, remission, and post-progression) and pre-treatment tumor samples were collected from 21 patients who received bevacizumab-containing first-line chemotherapy. Extracted DNA was sequenced by next-generation sequencing using a panel of 90 oncogenes. Candidate ctDNAs in plasma were validated using mutational data from matching tumors. ctDNAs encoding one to six trunk mutations were found in all 21 cases, and the mutant allele frequency (MAF) was distributed over a wide range (1-89%). Significant decreases in the MAF at remission and increases in the MAF after progression were observed (p < 0.001). Reduction in the MAF to below 2% in the remission period was strongly associated with better survival (16.6 vs. 32.5 months, p < 0.001). In two cases, mutations (in CREBBP and FBXW7 genes) were newly detected in ctDNA at a low frequency of around 1% in the post-progression period. The use of ctDNA allows elucidation of the tumor clonal repertoire and tumor evolution during anti-VEGF chemotherapy. Changes in ctDNA levels could be useful as predictive biomarkers for survival. Mutations newly detected in ctDNA in the late treatment period might reveal the rise of a minor tumor clone that may show resistance to anti-VEGF therapy.
Introduction
The combination of cytotoxic chemotherapeutics and targeted drugs has been regarded as the standard treatment for patients with metastatic colorectal cancer (mCRC). 1 Either addition of anti-epidermal growth factor receptor (EGFR) antibody or anti-vascular endothelial growth factor-A (VEGF-A) antibody to cytotoxic regimens has been demonstrated to improve survival. 2, 3 Despite remarkable advances in the development of therapies, the emergence of resistance eventually limits their effectiveness. For optimization of treatment strategies, further understanding of genetic events in patients during chemotherapy and the establishment of useful genomic biomarkers to guide the management of treatment are crucial. Plasma circulating tumor DNA (ctDNA) has been increasingly investigated as a promising application for genomic profiling of tumors. Unlike repeated tumor biopsy, which is not feasible in clinical practice, analysis of ctDNA obtained from peripheral blood could be used to less-invasively track changes in the genetic composition of molecularly and cellularly heterogeneous tumors. 4, 5 Furthermore, it was demonstrated that longitudinal monitoring of ctDNA effectively detects the emergence of RAS gene mutations induced by anti-EGFR therapy in an initially RAS-wild population. 6, 7 These additional genomic aberrations might be associated with tumor clonal evolution and selection that may occur at distinct metastatic sites as a response to treatment pressure. 8, 9 In contrast, little is known about ctDNA kinetics or alterations in its makeup during anti-VEGF chemotherapy, which has been broadly adopted as one of the common first-line chemotherapies for mCRC. The lack of knowledge regarding novel tumor genetic events during chemotherapy has long restricted optimal patient selection for anti-VEGF therapy. 10 Angiogenesis inhibitors, such as bevacizumab, cause substantial therapeutic stress to tumor cells, primarily inducing hypoxic stress. 11 Long-term exposure to anti-angiogenic agents may affect tumor genomic composition or trigger selection of a hypoxia-tolerant minor subpopulation of tumor cells. Several studies have reported increased tumor invasiveness in response to anti-angiogenic therapies in animal models. 12, 13 However, tracing tumor gene status during anti-VEGF chemotherapy in the clinical setting has been a major challenge. The aim of our study was to explore molecular events that may be associated with treatment outcome or development of resistance during anti-VEGF chemotherapy. We investigated dynamic changes in the amount and constitution of ctDNA in serial plasma samples of patients who received standard anti-angiogenic chemotherapy.
Materials and Methods

Patients
Patients were recruited prospectively for our study from January 2014 to January 2016 at Hiroshima Prefectural Hospital in Hiroshima, Japan. The study population consisted of 61 serial peripheral blood samples, matched tumor samples, and peripheral blood leukocytes from 21 patients with mCRC. All patients were treated with bevacizumab-containing cytotoxic chemotherapy as the first-line treatment for at least six months. Clinicopathological features of the patients in our study are shown in Supporting Information, Table S1 . Targeted next-generation sequencing (NGS) of DNA extracted from plasma samples, tumor tissues, and control lymphocytes identified somatic rearrangements. The Human Ethics Review Committees of Hiroshima University and Hiroshima Prefectural Hospital approved the study. All patients provided written informed consent.
Determination of time points for analysis
We set the following three time points for analysis of the samples: baseline (before the initiation of chemotherapy), remission, and post-progression. The timing of remission was determined by computed tomography (CT) findings with the most favorable response assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. In patients COL-001 and COL-021, two different plasma specimens were analyzed at the time of remission. The timing of progression was determined by discontinuation of cytotoxic chemotherapy plus bevacizumab (the end of the firstline oxaliplatin-based therapy in COL-001, 026, 030, 034, 044, 046-060, or the end of the second-line irinotecan-based therapy in the other patients).
Baseline mutations within the archival tumor tissue DNA of the primary tumor was extracted from five 10-lmthick slides that were made from the formalin-fixed paraffin embedded (FFPE) samples acquired at the time of initial diagnosis using the GeneRead DNA FFPE Kit (Qiagen, Germany). The quantity and quality of the FFPE-derived DNA samples were checked by calculation of the normalized DNA integrity score (DDCq) that was assessed with qPCR using the Agilent NGS FFPE QC Kit (Agilent, United States).
Control lymphocytes
Seven milliliters of peripheral venous blood were collected prior to the initiation of chemotherapy. The genomic DNA of lymphocytes was extracted and used as germline controls.
Cell-free DNA
Ten milliliters of peripheral venous blood were collected using EDTA as an anticoagulant at baseline, remission, and post-progression. The drawn blood was immediately processed to isolate plasma by a two-step centrifugation process: 3,500 rpm, for 10 min followed by 12,000 rpm for 10 min at 48C. Separated plasma was stored at 2808C prior to DNA extraction. Cell-free DNA was purified from 3 ml of plasma aliquots using QIAGEN Plasmid Plus Kits (Qiagen) according to the manufacturer's protocols. Cellfree DNA was eluted into 100 ll of buffer, quantified
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using Qubit HS (Thermo Fisher Scientific, US), and stored at 48C.
Target enrichment and next-generation sequencing
Cell-free DNA and DNA extracted from primary tumors and normal lymphocytes was fragmented and used for library construction according to the manufacturer's instructions. In all cases, 40 ng of cell-free DNA was prepared for sequencing. The exons of 90 oncogenes and the associated introns of 35 fusion oncogenes were enriched using the KAPA Hyperprep kit and the NCC oncopanel (Agilent, Supporting Information, Table S2 ). The resulting pooled libraries were quality control checked using the High Sensitivity D1000 ScreenTape System with the 2200 TapeStation Instrument (Agilent). Sequencing was performed with paired-end reads on the HiSeq 2500 platform (Illumina, US).
Variant Detection
Sequencing reads were aligned to the hg19/GRCh37 reference sequence and analyzed using the CLC Genomics Workbench (CLC bio, Denmark). PCR duplicates were removed and local realignment was performed using CLC to improve mapping quality prior to variant calling. To identify variants in plasma and primary tumor samples, the low frequency variant detection software in CLC was used. Called variants were considered germline mutations if they were called in the control lymphocytes or were found in the dbSNP 137 database, the HapMap database, or the 1000 Genomes Project. The remaining mutations in plasma samples were considered ctDNA candidates. To reduce the false positive rate, we set the cutoff values for ctDNA in plasma as follows: read depth > 200; number of mutant reads > 18; allele frequency of mutant reads > 0.5%; average quality > 20; and the ratio of forward reads to reverse reads > 10%. Identified ctDNAs were validated by detection of mutations in the sequence of matching primary tumor samples.
Disease burden and tumor markers
CT was performed at least bimonthly and disease response was evaluated by RECIST version 1.1. Tumor burden was calculated from a CT image using the sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) of one or two of the largest lesions in each metastatic site. The levels of serum carcinoembryonic antigen (CEA) and serum carbohydrate antigen 19-9 (CA19-9) were measured monthly. The maximum intervals between sampling of ctDNA and CT assessment or measurement of tumor markers were four weeks or two weeks, respectively.
Statistical analysis
The differences in mutant allele frequency at baseline and remission, or at remission and post-progression, were assessed using the Wilcoxon signed-rank test. Correlations between the variables were assessed using Spearman's rank correlation. Overall survival was estimated using KaplanMeier methods and differences between subgroups were 
Results
Constitution and dynamics of the ctDNA
In all 21 cases, ctDNA containing one to six somatic mutations per patient was identified in plasma samples at baseline (Fig. 1) . In the sequencing analysis, the coverage depth in targeted regions after the removal of PCR duplicates ranged from 888 to 5,449. Out of 52 ctDNAs identified at baseline, 30 (58%) were single nucleotide variants and 22 (42%) were nucleotide insertions or deletions (Table 1) . No actionable gene fusions were detected. There was some diversity in the ctDNAs in terms of the cellular processes/signaling pathways with which the corresponding genes are known to be involved, and this diversity may underlie in part the molecular characterization of each tumor. The concentration of ctDNA, which was determined based on assessment of the mutant allele frequency (MAF), fluctuated dynamically throughout the treatment period. Significant decreases in the MAF at remission by chemotherapy and increases in the MAF after disease progression that were accompanied by the appearance of resistance to chemotherapy were observed (Fig. 2) . Of the 52 ctDNAs identified at baseline, 48 ctDNAs were detectable post-progression; the four mutations that were not detected post-progression were APC in patient COL-023, SETD2 and ARID1A in patient COL-025, and APC in patient COL-058.
ctDNA, tumor burden, and tumor markers
There was a positive correlation between the MAF and tumor load; however, this correlation was diminished when the MAF and tumor burden data were limited to the time of remission (Fig. 3a) . On the other hand, there were no correlations between the MAF and tumor markers at any time points (Fig. 3b and c) . In addition, the levels of CEA and CA19-9 were not elevated at any time point in three patients (COL-023, COL-025, COL-030).
ctDNA as a predictive biomarker for survival
Reduction in the MAF to below the median value in the remission period was strongly associated with better survival (16.6 vs. 32.5 months, p < 0.001, Fig. 4) . Even in the cases in which the patient had multiple ctDNAs, the MAF had decreased to <2% in the long-term survivors. The MAF at remission was an independent predictor for survival following multivariate Cox regression analysis adjusted by clinicopathological parameters (Supporting Information, Table S3 ). Although higher MAF at baseline seemed to be associated with worse survival, an appropriate MAF threshold was not found because of the wide distribution and variability of MAFs among the cases. The median duration between treatment initiation and plasma sampling at remission was 4.5 months in the MAF <2% group and 4 months in the MAF 2% group. Of note, despite the relatively high MAFs at baseline in patient COL-001 (Fig. 5) , ctDNA had become undetectable in response to bevacizumab-containing chemotherapy, whereas only a moderate decline in tumor markers was observed. The MAFs had rebounded to a high level at the post-progression time point; however, the subsequent EGFR-blockade chemotherapy and successful resection of liver metastases indeed prolonged the patient's survival for up to 32.5 months.
Mutations newly detected at post-progression
In two patients, we detected a mutation at a low frequency of around 1% in the post-progression period (Fig. 6) . In one patient, a mutation in the cAMP-response element-binding protein-binding protein gene (CREBBP) emerged after concentrated exposure to bevacizumab-containing chemotherapy. This patient already showed a truncal mutation in MET from baseline, for which the level mirrored the disease control. In the other patient, COL-034, mutation of the F-box and WD repeat domain-containing gene (FBXW7) was detected for the first time in the late treatment period. This patient already showed mutations in four other genes with respect to baseline. 
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Discussion
The present study demonstrated in several ways the utility of serial sampling of ctDNA over a long clinical course in terms of guiding anti-VEGF therapy for mCRC. Targeted NGS of plasma DNA may be sufficient to provide information about tumor genotype, to monitor disease control, and to predict survival. ctDNA that is newly detected after therapy could provide clues to uncovering the mechanism of resistance to angiogenesis inhibitors.
We first showed the simple dynamics of ctDNA over the long-term clinical course, in which the level of ctDNA declined in response to chemotherapy and thereafter increased again, suggesting the acquisition of resistance. The most recent ctDNA study, 14 which employed a multiregional approach and a large cancer panel, indicated that ctDNA detection displayed high sensitivity and accuracy for the molecular assessment of pancreatic cancer, confirming that ctDNA analysis is a feasible method for tumor analysis. High levels of truncal ctDNAs that represent the DNA mutations in the majority of tumor cells 15 are suitable for monitoring tumors during follow-up without drop out. In most of the previous landmark reports, the genes that were screened were limited to the area of interest and were associated with the RAS-RAF-MAPK signaling pathway. 16, 17 Furthermore, reported ctDNA data represented only a cross-section of ctDNAs present at the initial diagnosis 18 or at post-treatment. 16 Our less-biased NGS approach to identification of ctDNAs indicates that wide-spectrum, longitudinal ctDNA analysis may be a promising quantitative measurement method for monitoring disease. It is also expected that this approach may provide an alternative to the measurement of tumor markers, which often do not accurately reflect disease status due to lack of sensitivity and specificity. 19 Next, we focused on determination of whether the level of ctDNA at remission could be a biomarker for patient survival. A recent study showed a trend for longer progressionfree survival in patients with mCRC who experienced a 10-fold or greater decrease in ctDNA at the end of the first cycle of chemotherapy compared to baseline. 18 This early indicator of survival should certainly be regarded as a valuable survival indicator. However, chemotherapy for mCRC is so effective in the first-line setting that it generally continues for over half a year and sometimes it is integrated with other procedures including surgery. We therefore considered that analysis of the ctDNA level at a later phase accompanied by the most favorable therapeutic response would be a more practical and reasonable indicator for optimization of treatment. Although the mechanism of ctDNA release from a tumor is not fully understood, it has been strongly suggested that it is related to tumor cell apoptosis. 20 We consider that a decreased level of ctDNA may be linked to a "silent" status of the tumor that reflects not only suppression of cancer cell growth but also suppression of apoptosis. It is likely that the degree of the decrease in ctDNA might be a surrogate for the depth of the tumor response to therapy. 21 Finally, we proposed a model in which newly detected mutations at the "post-progression" time point might explain acquired resistance to hypoxic conditions under anti-VEGF therapy. One of these newly detected mutations, p.R1347W, is located in the coding exon 31 of CREBBP, which is part of the histone acetyltransferase (HAT) domain that plays a pivotal role in the maintenance of cellular epigenetic equilibrium. 22 HAT missense mutations can lead to a histone deacetylase dominant condition, gene silencing, and consequent tumorigenesis. 23, 24 The second newly identified mutation, p.H455Q, occurs inside a WD-40 domain. Mutations in WD-40 domains are thought to interfere with the function of the tumor suppressor FBXW7 protein, which functions as a component of ubiquitin ligase. 25 Loss of FBXW7 function reduces turnover of oncogenic substrates such as MYC, Notch, 26 and ENO1, 27 which confers metabolic advantages to tumor cells under hypoxic conditions. A previous study reported that mutant RAS alleles that were newly detected after disease progression in mCRC that became refractory to anti-EGFR antibody were distributed at a very low concentration (0.02-10%). 17 It was possible to detect most of these mutations by using supersensitive assays such as BEAMing 17 or digital PCR. 28 It is unclear why the levels of ctDNA derived from actively resistant lesions are present at such a low concentration. However, the observed frequency of private mutations of around 1% in our study could be evidence of clonal selection under treatment pressure. Compared to a previous report in which the sensitivity of ctDNA detection was unsatisfactory, 29 our careful patient selection, prompt plasma isolation (< 30 min), and strict algorithm to exclude sequencing errors should ensure the detection of low frequency ctDNAs. Although we have not carried out functional validation of the late-emerging ctDNA mutations found in our study, there have been a number of reports that showed the importance of both CREBBP 30, 31 and FBXW7 32,33 as tumor suppressor genes by using knockdown experiments in various cancer cell lines or animal-cancer models. Our hypothesis regarding the association of CREBBP or FBXW7 mutation with tolerance to hypoxia is consistent with the cancer biology demonstrated in those studies. Since resistance mechanisms are thought to be specific to individual patients, we think that further accumulation of newly detected mutations in a larger cohort is important. Our pilot study has several limitations. Although sample collection was performed prospectively and the collected blood volume of 10 ml was sufficient for analysis, the sample size was small. To clarify the correlation of ctDNA and treatment effect, patients without beneficial response to anti-VEGF therapy were excluded. Therefore, it is unclear whether a similar comprehensive approach might be feasible for patients with oligometastatic lesions or patients with intrinsic resistance. The second limitation is the absence of a control arm. The exposure to chemotherapy without targeted drugs may in fact alter the mutational status of the tumor. 34 Since bevacizumab is always used in combination with chemotherapeutics, inspection of gene alteration limited to the effect of bevacizumab administration alone is not possible and would be meaningless in the clinical setting. In the near future, technological advances will allow frequent ctDNA analyses during therapy with reasonable costs. Prospective trials with proper treatment stratification and with adequate power for statistical analysis are warranted to overcome these limitations. 35 In conclusion, we proposed the use of ctDNA as a biomarker for a patient population that has not been tested in previous studies. We believe that accumulation of genetic information obtained by serial ctDNA profiling could contribute to the construction of precision medicine for patients with mCRC. 
